2:06 PM
Jan 09, 2018
 |  BC Innovations  |  Distillery Therapeutics



Patient sample and cell culture studies suggest a synthetic transcription elongation factor that induces FXN expression could help treat Friedreich’s ataxia. The synthetic molecule consists of a small molecule bromodomain containing 4 (BRD4) ligand tool compound conjugated to...

Read the full 173 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$18 USD
More Info >